Hepatitis C: Practice Essentials, Background, Pathophysiology. Maticic M. Lichen planus in hepatitis C virus infection: an early marker that may save lives. Acta Dermatovenerol Alp Panonica Adriat. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Mar 1. 1. 3. 55(9. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1. Ann Intern Med. 2. Feb 2. 1. 1. 56(4): 2. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1. 98. Nov 3. 0. 3. 21(2. Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV- 1 and HCV infections among antibody- negative blood donors by nucleic acid- amplification testing. N Engl J Med. 2. 00. Aug 1. 9. 3. 51(8): 7. Rischitelli G, Harris J, Mc. Cauley L, Gershon R, Guidotti T. The risk of acquiring hepatitis B or C among public safety workers: a systematic review. Am J Prev Med. 2. Yeung LT, King SM, Roberts EA. Mother- to- infant transmission of hepatitis C virus. Alter MJ, Kruszon- Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1. N Engl J Med. 1. 99. Aug 1. 9. 3. 41(8): 5. El- Serag HB, Davila JA, Petersen NJ, Mc. Running a fever, especially a high fever, is a sign that your body is fighting an infection following gallbladder surgery. ICD-9-CM codes are used in medical billing and coding to describe diseases, injuries, symptoms and conditions. ICD-9-CM V11.8 is one of thousands of ICD-9-CM codes. Glynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2. Nov 1. 8. 1. 39(1. The burden of hepatitis C in the United States. Suppl 1): S3. 0- 4. Hepatitis C: global prevalence. Wkly Epidemiol Rec. Nov 1. 4. 7. 2(4. Nakashima K, Ikematsu H, Hayashi J, Kishihara Y, Mutsutake A, Kashiwagi S. Digestive Disorders Overview. Common digestive problems include heartburn/GERD, IBD, and IBS. Symptoms may include bloating, diarrhea, gas, stomach pain, and stomach. Is there such a thing as adrenal fatigue? Answers from Todd B. Nippoldt, M.D. Adrenal fatigue is a term applied to a collection of nonspecific symptoms, such as body. Test Highlight. Celiac Disease Comprehensive Panel : Clinical Use: Diagnose celiac disease in patients 4 years of age and older. Intrafamilial transmission of hepatitis- C virus among the population of an endemic area of Japan. Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of Southern Italy. Kiyosawa K, Tanaka E, Sodeyama T, et al. Transmission of hepatitis C in an isolated area in Japan: community- acquired infection. The South Kiso Hepatitis Study Group. Gastroenterology. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Seeff LB, Miller RN, Rabkin CS, et al. C virus infection in healthy young adults. Ann Intern Med. 2. Jan 1. 8. 1. 32(2): 1. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood- donor screening. N Engl J Med. 1. 99. Sep 1. 6. 3. 41(1. Obando J, Tortorelli K, Banner B, Stefancyk D, Bonkovsky HL. Iron: the major HFE gene mutation and chronic hepatitis C . Gastroenterology. Banner BF, Karamitsios N, Smith L, Bonkovsky HL. Enhanced phenotypic expression of alpha- 1- antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol. Hu KQ, Tong MJ. The long- term outcomes of patients with compensated hepatitis C virus- related cirrhosis and history of parenteral exposure in the United States. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Mc. Combs J, Matsuda T, Tonnu- Mihara I, et al. The risk of long- term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 1. Hepatitis C viral suppression reduces liver morbidity, death. Medscape Medical News from Web. MD. Available at http: //www. Nov 1. 5; Accessed: November 1. Everson GT, Weinberg H. Living With Hepatitis C: A Survivor's Guide. Long Island City, New York: Hatherleigh Health; 2. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C- infected grafts in liver transplantation. Liver Transpl. 9(1. S4. 8- 5. 1. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1. MMWR Recomm Rep. 2. Aug 1. 7. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 4. Cacoub P, Renou C, Rosenthal E, et al. The GERMIVIC. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 3. Medicine (Baltimore). Dervis E, Serez K. The prevalence of dermatologic manifestations related to chronic hepatitis C virus infection in a study from a single center in Turkey. Acta Dermatovenerol Alp Panonica Adriat. Hepatitis C point- of- care tests are highly accurate. Medscape Medical News from Web. MD. Available at http: //www. Oct 1. 5; Accessed: November 1. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point- of- care screening tests for hepatitis C: a systematic review and meta- analysis. Ann Intern Med. 2. Oct 1. 6. 1. 57(8): 5. Hepatitis C: USPSTF recommends all baby boomers be screened. Medscape Medical News from Web. MD. Available at http: //www. Jun 2. 4 2. 01. 3; Accessed: Jun 2. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 1. Expanded hepatitis C virus screening recommendations promote opportunities for care and cure. Ann Intern Med. 1. Baby boomer Hep C screening practical in emergency department. Medscape Medical News from Web. MD. Available at http: //www. Mar 1. 2; Accessed: April 1, 2. Galbraith JW, Morgan J, Rodgers J, et al. High yield and feasibility of baby boomer birth cohort HCV screening in two urban, academic emergency departments . Presented at: International Conference on Viral Hepatitis (ICVH); March 1. New York, NY. FDA approves rapid test for antibodies to hepatitis C virus. FDA News Release. June 2. 5, 2. 01. Available at http: //www. News. Events/Newsroom/Press. Announcements/ucm. Crane M. FDA approves first genotyping test for patients with HCV. Medscape Medical News from Web. MD. Available at http: //www. Jun 2. 0; Accessed: June 2. US Food and Drug Administration. FDA approves first genotyping test for patients with hepatitis C virus. FDA News Release. Jun 2. 0. Available at http: //www. News. Events/Newsroom/Press. Announcements/ucm. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL2. B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 5. Della Rossa A, Tavoni A, Baldini C, Bombardieri S. Mixed cryoglobulinemia and hepatitis C virus association: ten years later. Isr Med Assoc J. US Food and Drug Administration. Premarket notification: Hepatiq. Available at http: //www. ID=K1. 42. 89. 1. Accessed: January 1. Business Wire. Hepatiq receives FDA clearance. Hepatiq. com. Available at http: //www. Dec 1. 9; Accessed: January 1. HALT- C (Hepatitis C Antiviral Long- term Treatment against Cirrhosis) trial website. National Institute of Diabetes and Digestive and Kidney Diseases. Available at http: //archives. Accessed: January 1. Recommendations for testing, managing, and treating hepatitis C. HCV Guidance. Available at http: //www. Accessed: June 3. Jezequel C, Bardou- Jacquet E, Desille Y, et al. Survival of patients infected by chronic hepatitis C and F0. F1 fibrosis at baseline after a 1. Presented at: 5. 0th Annual Meeting of the European Association for the Study of the Liver (EASL); April 2. Vienna, Austria. US Food and Drug Administration. FDA approves Sovaldi for chronic hepatitis C. FDA News Release. Available at http: //www. News. Events/Newsroom/Press. Announcements/ucm. Dec 6; Accessed: December 2. Tucker ME. FDA approves 'game changer' hepatitis C drug sofosbuvir. Medscape Medical News from Web. MD. Available at http: //www. Dec 6; Accessed: December 2. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non- responders to pegylated interferon and ribavirin and treatment- naive patients: the COSMOS randomised study. Nov 1. 5. 3. 84(9. US Food and Drug Administration. FDA approves Viekira Pak to treat hepatitis C. FDA News Release. Available at http: //www. News. Events/Newsroom/Press. Announcements/ucm. Dec 1. 9; Accessed: April 6, 2. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non- A, non- B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1. 98. Dec 1. 8. 3. 15(2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double- blind, placebo- controlled trial. N Engl J Med. 1. 98. Nov 3. 0. 3. 21(2. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa- 2b. N Engl J Med. 2. 00. Nov 1. 5. 3. 45(2. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa- 2a in patients with chronic hepatitis C. N Engl J Med. 3. 43(2. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa- 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 3. 43(2. Mc. Hutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa- 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1. 99. Nov 1. 9. 3. 39(2. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha. C virus. International Hepatitis Interventional Therapy Group (IHIT). Up. To. Date Subscriptions for Residents, Fellows and Students. Get the Benefit of an Up. To. Date Subscription at a Fraction of Our Full Professional Rate. Whether or not your hospital provides access to Up. To. Date. As a trainee, you need a current and reliable clinical decision support resource to help you answer questions quickly and easily at the point of care. Up. To. Date is also ideal to use when preparing for rounds and presentations. Trainees who provide a valid proof of status receive our low trainee subscription prices. Up. To. Date to a colleague. Base Subscription. Up. To. Date Online: All individual subscriptions include Up. To. Date Online, which provides access to Up. To. Date from any Internet browser on a computer or mobile device with a personal user name and password. Individual subscribers can also download free on- demand Apps. Optional Add- ons. Up. To. Date Mobile. Complete. Simply use a Wi- Fi connection to download the full content of Up. To. Date to your device and find clinical recommendations even without a network connection!*Start taking advantage of the unparalleled benefits Up. To. Date offers. Subscribe today. An individual subscription is required for access to Up. To. Date through our Mobile Apps. Explore Up. To. Date options for educators here.* Up. To. Date Mobile. Complete. For individual subscribers, there is a fee associated with upgrading your subscription to include Mobile. Complete. Up. To. Date Anywhere users should check with your organization to see if they provide this mobile option. Wi- Fi access is required for initial download and full content updates. Up. To. Date Individual Subscriber Survey, October 2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |